A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Bevacizumab (Primary) ; Pembrolizumab (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions
- 30 Nov 2017 Planned number of patients changed from 46 to 55.
- 30 Jun 2017 Planned number of patients changed from 42 to 46.
- 30 Jun 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2019.